vida: extract claims from 2026-05-03-lancet-semalco-semaglutide-aud-rct-results

- Source: inbox/queue/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions.md

@@ -10,12 +10,16 @@ agent: vida
 scope: causal
 sourcer: Breedvelt, Warren, Segal, Kuyken, Bockting — JAMA Psychiatry
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]]"]
-related:
+related: ["Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication", "cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions", "antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse"]
-- Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
+reweave_edges: ["Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication|related|2026-04-12"]
-reweave_edges:
-- Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication|related|2026-04-12
 ---
 
 # Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation
 
 Individual participant data meta-analysis of RCTs comparing psychological intervention during/after antidepressant tapering versus continued medication found that CBT and continued antidepressant medication (ADM-c) were both superior to discontinued medication in preventing relapse over 12 months, and critically, CBT and continued medication did not differ significantly from each other in relapse prevention. Antidepressant discontinuation produced 34.81% relapse at 6 months and 45.12% at 12 months, while CBT after/during tapering provided protection comparable to continued medication. The mechanism is skill acquisition: CBT teaches cognitive and behavioral strategies that patients retain after therapy ends, providing 'enduring effects that extend beyond the end of treatment.' This finding has been replicated across multiple meta-analyses including the December 2025 Lancet Psychiatry NMA covering 76 RCTs and 17,000+ adults. No clinical moderators were associated with differential risk—the CBT advantage holds across patient subgroups. This represents a fundamental difference from metabolic interventions like GLP-1 agonists, where there is no 'skill analog' that allows patients to maintain benefits after drug cessation—you cannot do 'GLP-1 skills training' that substitutes for continuous pharmacotherapy. The contrast reveals that behavioral/cognitive interventions can escape the continuous-treatment model through durable skill acquisition, while pharmacological interventions require ongoing delivery to maintain effect.
+
+## Extending Evidence
+
+**Source:** SEMALCO trial, The Lancet 2026
+
+SEMALCO trial design (both arms received standard CBT) demonstrates semaglutide's 41% reduction in heavy drinking days is additive to behavioral therapy, not a replacement. This supports combination therapy model where pharmacological dopamine modulation complements skill-based relapse prevention.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -81,3 +81,10 @@ Concurrent psychotropic medication use (antidepressants, benzodiazepines) shows
 **Source:** The Lancet 2026, EVOKE/EVOKE+ Phase 3 failure
 
 EVOKE/EVOKE+ Alzheimer's failure provides critical boundary evidence for GLP-1 CNS mechanism specificity. Semaglutide succeeds in addiction (VTA dopamine reward circuits) but fails in neurodegeneration (amyloid/tau pathways), demonstrating that GLP-1 receptor activation produces pathway-specific effects rather than broad neuroprotection. This supports the mesolimbic dopamine mechanism for addiction while ruling out generalized CNS benefit claims.
+
+
+## Supporting Evidence
+
+**Source:** SEMALCO trial, The Lancet 2026
+
+SEMALCO Phase 2 RCT (N=108, 26 weeks) demonstrated semaglutide 2.4mg weekly achieved NNT 4.3 for AUD in comorbid obesity population, outperforming all FDA-approved AUD medications (NNT ≥7). Objective blood-alcohol biomarkers confirmed self-reported 41% reduction in heavy drinking days. Secondary finding: concurrent cigarette use reduction suggests cross-reward-circuit effects beyond AUD-specific mechanisms.

domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: "Phase 2 RCT shows semaglutide 2.4mg weekly reduces heavy drinking days 41% vs 26% placebo with NNT 4.3, outperforming all FDA-approved AUD medications in treatment-seeking patients with AUD and obesity"
+confidence: likely
+source: SEMALCO trial, The Lancet 2026, Mental Health Center Copenhagen
+created: 2026-05-03
+title: Semaglutide demonstrates superior AUD efficacy to all approved medications (NNT 4.3 vs 7+) in comorbid obesity population extending GLP-1 therapeutic scope from metabolic to behavioral health
+agent: vida
+sourced_from: health/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md
+scope: causal
+sourcer: The Lancet (SEMALCO trial team)
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial"]
+---
+
+# Semaglutide demonstrates superior AUD efficacy to all approved medications (NNT 4.3 vs 7+) in comorbid obesity population extending GLP-1 therapeutic scope from metabolic to behavioral health
+
+The SEMALCO trial (N=108, 26 weeks, double-blind RCT) demonstrated semaglutide 2.4mg weekly achieved 41.1% reduction in heavy drinking days from baseline (95% CI −48.7 to −33.5) versus 26.4% for placebo (−34.1 to −18.6), with treatment difference of −13.7 percentage points (p=0.0015). This translates to NNT of 4.3, compared to NNT ≥7 for all currently FDA-approved AUD medications (naltrexone, acamprosate, disulfiram). The finding was confirmed by objective blood-alcohol biomarkers, not just self-report. Both arms received standard CBT, so the effect is additive to behavioral therapy. Secondary outcomes showed semaglutide significantly reduced drinks per drinking day and weekly alcohol craving, though not total drinking days. A subgroup analysis found greater reductions in cigarettes/day among concurrent smokers, suggesting GLP-1 may act across reward circuits simultaneously rather than AUD-specifically. Critical scope limitations: (1) comorbid obesity required (BMI ≥30), so findings cannot extrapolate to AUD without obesity; (2) both arms received CBT, so semaglutide monotherapy efficacy is unknown; (3) 26-week duration provides no long-term durability data; (4) single-center design limits generalizability. Phase 3 trials are underway (NCT05520775, NCT07218354) but timelines are not publicly disclosed. This is the largest RCT of semaglutide for AUD to date and represents the most clinically significant AUD pharmacotherapy finding in a decade if Phase 3 confirms.

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.m
 scope: causal
 sourcer: Hendershot CS et al.
 supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"]
+related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
 ---
 
 # Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
@@ -31,3 +31,10 @@ Meta-analysis confirms semaglutide as best-performing agent for alcohol reductio
 **Source:** Qeadan F et al., Addiction 2025
 
 Real-world observational data from 817,309 AUD patients (5,621 with GLP-1 RA) shows 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) over 24 months, consistent with Hendershot RCT findings. Effect maintained across T2DM (IRR 0.51), obesity (IRR 0.58), and combined conditions (IRR 0.58) subgroups. Provides population-scale corroboration of the VTA dopamine mechanism hypothesis, though observational confounding limits causal inference.
+
+
+## Supporting Evidence
+
+**Source:** SEMALCO trial, The Lancet 2026
+
+SEMALCO trial provides Phase 2 RCT confirmation with 41.1% reduction in heavy drinking days (treatment difference −13.7 percentage points, p=0.0015) and significant reductions in drinks per drinking day and weekly alcohol craving. Biomarker validation strengthens mechanistic interpretation.

inbox/archive/health/2026-05-03-lancet-semalco-semaglutide-aud-rct-results.md

@@ -7,10 +7,13 @@ date: 2026-04-01
 domain: health
 secondary_domains: []
 format: research-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-03
 priority: high
 tags: [GLP-1, semaglutide, alcohol-use-disorder, AUD, behavioral-health, addiction-medicine, RCT, clinical-trial]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content